CD19-targeted CAR T-cell therapy shows a 65% response rate in Richter transformation, with median progression-free survival of 8 months and overall survival of 14.4 months. Early response and age are ...
The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback